DAQ-DcpSi therapeutic benefit in SMA mice is not the result of lysosomotropism and is accompanied by significant and substantial increases in Smn transcripts but no change in Smn protein. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.